Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1802 with Adebrelimab in Advanced Solid Tumors
NCT05794477Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1802 in solid tumor (advanced stage), sponsored by Hengrui Therapeutics. Started Apr 2023; status: recruiting.
02
Drugs
SHR-1802
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05794477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05794477.